Infections with Y. pseudotuberculosis can lead to severe complications, particularly in vulnerable populations such as children and the immunocompromised. By harnessing the latest scientific advancements and employing rigorous preclinical research methodologies, we are committed to advancing the frontier of Y. pseudotuberculosis infection vaccines and therapies.
Introduction to Yersinia Pseudotuberculosis Infection
Yersinia pseudotuberculosis is a pathogenic bacterium belonging to the Yersinia genus, which also includes the infamous Yersinia pestis, the causative agent of plague. Y. pseudotuberculosis primarily causes gastrointestinal infections in humans and is responsible for a condition known as yersiniosis. This bacterium is typically transmitted through contaminated food or water and can lead to symptoms such as fever, abdominal pain, and diarrhea. The infection is particularly concerning due to its zoonotic potential, affecting a variety of animal hosts, including rodents, which act as reservoirs.
Fig.1 Colonization patterns of Y. pseudotuberculosis during acute and persistent infection. (Heine W., et al., 2018)
Vaccine Development for Yersinia Pseudotuberculosis Infection
- Live Attenuated Vaccines
Live attenuated vaccines have been at the forefront of vaccine development against Y. pseudotuberculosis. These vaccines utilize weakened strains of the bacteria that retain their ability to replicate and stimulate an immune response without causing disease. The VTnF1 strain, for instance, is an attenuated Y. pseudotuberculosis vaccine candidate that has demonstrated high efficacy in inducing protective immunity against plague and yersiniosis in murine models.
- Subunit and Recombinant Vaccines
Subunit and recombinant vaccines focus on specific antigens of Y. pseudotuberculosis that can trigger an immune response. The F1-V vaccine, composed of the F1 capsular protein and V antigen (LcrV) of Y. pestis, has shown promise in providing protection against plague. These types of vaccines are advantageous due to their defined composition and reduced risk of reverting to a virulent form.
Therapeutics Development for Yersinia Pseudotuberculosis Infection
Monoclonal Antibodies
These therapies can be designed to target specific virulence factors or to enhance the immune response against the pathogen.
Antibiotic Therapy
Commonly prescribed antibiotics include aminoglycosides, tetracyclines, and fluoroquinolones.
Immunotherapy
researchers are exploring various modalities, including cytokine therapies and immune checkpoint inhibitors.
Our Services
At our company, we are committed to advancing the development of vaccines and therapeutics for Yersinia pseudotuberculosis infections. Our multidisciplinary team of experts employs cutting-edge technologies and methodologies to create innovative solutions tailored to meet the needs of our clients.
Disease Models
- Oral Gavage Models
- Bread-Feeding Models: The bacterial culture is resuspended in melted butter and soaked into small pieces of white bread.
We offer comprehensive services that encompass vaccine formulation, and preclinical research. Our focus on collaboration ensures that we work closely with stakeholders to translate scientific discoveries into effective interventions. If you are interested in our services, please feel free to contact us.
References
- Heine, Wiebke, et al. "Loss of CNFY toxin-induced inflammation drives Yersinia pseudotuberculosis into persistency." PLoS pathogens 14.2 (2018): e1006858.
- Singh, Amit K., Roy Curtiss III, and Wei Sun. "A recombinant attenuated Yersinia pseudotuberculosis vaccine delivering a Y. pestis YopENt138-LcrV fusion elicits broad protection against plague and yersiniosis in mice." Infection and Immunity 87.10 (2019): 10-1128.
- Kimura, Jiro, and Kiyoshi Sasaki. "Yersinia pseudotuberculosis infection intractable by antibiotics: A rare case report." International Journal of Surgery Case Reports 21 (2016): 139-141.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
